Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $26.6 million.

  • Gyre Therapeutics' Receivables - Net rose 3599.14% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.6 million, marking a year-over-year increase of 3599.14%. This contributed to the annual value of $24.0 million for FY2024, which is 5802.94% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Receivables - Net is $26.6 million, which was up 3599.14% from $25.1 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Receivables - Net peaked at $26.6 million during Q3 2025, and registered a low of $564000.0 during Q1 2022.
  • Over the past 5 years, Gyre Therapeutics' median Receivables - Net value was $15.2 million (recorded in 2023), while the average stood at $12.1 million.
  • Per our database at Business Quant, Gyre Therapeutics' Receivables - Net crashed by 4512.53% in 2021 and then surged by 84257.43% in 2022.
  • Gyre Therapeutics' Receivables - Net (Quarter) stood at $1.8 million in 2021, then surged by 842.57% to $17.1 million in 2022, then decreased by 11.51% to $15.2 million in 2023, then soared by 58.03% to $24.0 million in 2024, then rose by 10.88% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $25.1 million for Q2 2025, and $22.3 million during Q1 2025.